This Article Full Text Full Text (PDF) Purchase Article View Shopping Cart Alert me when this article is cited Alert me if a correction is posted Services Email this article to a colleague Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Save to my personal folders Download to citation manager Rights & Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Loprinzi, C. L. Articles by Thomé, S. D. Search for Related Content PubMed PubMed Citation Articles by Loprinzi, C. L. Articles by Thomé, S. D. Social Bookmarking                            What's this?

Understanding the Utility of Adjuvant Systemic Therapy for Primary Breast Cancer

From the Mayo Clinic, Rochester, MN.

Address reprint requests to Charles L. Loprinzi, MD, Division of Medical Oncology, Mayo Clinic, 200 First St SW, Rochester, MN 55905; email cloprinzi{at}mayo.edu

PURPOSE: Physicians and patients require quantitative information on the expected benefits of adjuvant therapy for primary breast cancer to make appropriate treatment decisions. To date, there has not been any widely available method for estimating the benefits from adjuvant systemic therapy, in terms of long-term disease-free survival probabilities, in patients with primary breast cancer.

METHODS: Baseline prognostic information for primary breast cancer patients was estimated by asking 11 breast cancer specialists to complete a questionnaire on baseline prognosis and then using mean values. Data on the relative benefits of adjuvant therapy were culled from systematic reviews and randomized controlled trials. A computer algorithm was developed to calculate 10-year absolute outcome data. Results from this evaluation were compared with a previously described actuarial algorithm.

RESULTS: Individual prognostic estimates varied within a group of breast cancer specialists, but mean values of their estimates closely followed published data. Translation of expected benefits of adjuvant therapy from relative to absolute terms was performed with a simple computer algorithm. The data were translated into tabular forms to facilitate user-friendly clinical use.

CONCLUSION: The provided data should facilitate a better understanding of the absolute magnitude of benefit for available systemic adjuvant therapies in individual women with primary breast cancer. This should allow patients to make more informed decisions about their options.

CiteULike    Complore    Connotea    Del.icio.us    Digg    Facebook    Reddit    Technorati    Twitter    What's this?

This article has been cited by other articles:

				S. Ahn, B. Park, D. Noh, S. Nam, E. Lee, M. Lee, S. Kim, K. Lee, S. Park, and Y. Yun Health-related quality of life in disease-free survivors of breast cancer with the general population Ann. Onc., January 1, 2007; 18(1): 173 - 182. [Abstract] [Full Text] [PDF]

				I. A. Olivotto, C. D. Bajdik, P. M. Ravdin, C. H. Speers, A. J. Coldman, B. D. Norris, G. J. Davis, S. K. Chia, and K. A. Gelmon Population-Based Validation of the Prognostic Model ADJUVANT! for Early Breast Cancer J. Clin. Oncol., April 20, 2005; 23(12): 2716 - 2725. [Abstract] [Full Text] [PDF]

				T. J. Whelan and C. Loprinzi Physician/Patient Decision Aids for Adjuvant Therapy J. Clin. Oncol., March 10, 2005; 23(8): 1627 - 1630. [Full Text] [PDF]

				A. B. Benson III, D. Schrag, M. R. Somerfield, A. M. Cohen, A. T. Figueredo, P. J. Flynn, M. K. Krzyzanowska, J. Maroun, P. McAllister, E. Van Cutsem, et al. American Society of Clinical Oncology Recommendations on Adjuvant Chemotherapy for Stage II Colon Cancer J. Clin. Oncol., August 15, 2004; 22(16): 3408 - 3419. [Abstract] [Full Text] [PDF]

				S. Gill, C. L. Loprinzi, D. J. Sargent, S. D. Thome, S. R. Alberts, D. G. Haller, J. Benedetti, G. Francini, L. E. Shepherd, J. Francois Seitz, et al. Pooled Analysis of Fluorouracil-Based Adjuvant Therapy for Stage II and III Colon Cancer: Who Benefits and by How Much? J. Clin. Oncol., May 15, 2004; 22(10): 1797 - 1806. [Abstract] [Full Text] [PDF]

				S. K. Chia, C. H. Speers, C. J. Bryce, M. M. Hayes, and I. A. Olivotto Ten-Year Outcomes in a Population-Based Cohort of Node-Negative, Lymphatic, and Vascular Invasion-Negative Early Breast Cancers Without Adjuvant Systemic Therapies J. Clin. Oncol., May 1, 2004; 22(9): 1630 - 1637. [Abstract] [Full Text] [PDF]

				C. Chao, J. L. Studts, T. Abell, T. Hadley, L. Roetzer, S. Dineen, D. Lorenz, A. YoussefAgha, and K. M. McMasters Adjuvant Chemotherapy for Breast Cancer: How Presentation of Recurrence Risk Influences Decision-Making J. Clin. Oncol., December 1, 2003; 21(23): 4299 - 4305. [Abstract] [Full Text] [PDF]

				M. Extermann, G. Albrand, H. Chen, S. Zanetta, R. Schonwetter, G. B. Zulian, A. Cantor, and J.-P. Droz Are Older French Patients As Willing As Older American Patients to Undertake Chemotherapy? J. Clin. Oncol., September 1, 2003; 21(17): 3214 - 3219. [Abstract] [Full Text] [PDF]

				C. E. Holmes and H. B. Muss Diagnosis and Treatment of Breast Cancer in the Elderly CA Cancer J Clin, July 1, 2003; 53(4): 227 - 244. [Abstract] [Full Text]

				L. Pusztai, M. Ayers, J. Stec, and G. N. Hortobagyi Clinical Application of cDNA Microarrays in Oncology Oncologist, June 1, 2003; 8(3): 252 - 258. [Abstract] [Full Text] [PDF]

				T. Whelan, C. Sawka, M. Levine, A. Gafni, L. Reyno, A. Willan, J. Julian, S. Dent, H. Abu-Zahra, E. Chouinard, et al. Helping Patients Make Informed Choices: A Randomized Trial of a Decision Aid for Adjuvant Chemotherapy in Lymph Node-Negative Breast Cancer J Natl Cancer Inst, April 16, 2003; 95(8): 581 - 587. [Abstract] [Full Text] [PDF]

				G. Sonpavde Communicating the Value of Adjuvant Chemotherapy J. Clin. Oncol., March 1, 2003; 21(5): 948 - 949. [Full Text] [PDF]

				C. A. Bunnell and E. P. Winer Lumping Versus Splitting: The Splitters Take This Round J. Clin. Oncol., September 1, 2002; 20(17): 3576 - 3577. [Full Text] [PDF]

				S. D. Thome, C. L. Loprinzi, and M. P. Heldebrant Determination of Potential Adjuvant Systemic Therapy Benefits for Patients With Resected Cutaneous Melanomas Mayo Clin. Proc., September 1, 2002; 77(9): 913 - 917. [Abstract] [PDF]

				P. A. Ganz, K. A. Desmond, B. Leedham, J. H. Rowland, B. E. Meyerowitz, and T. R. Belin Quality of Life in Long-Term, Disease-Free Survivors of Breast Cancer: a Follow-up Study J Natl Cancer Inst, January 2, 2002; 94(1): 39 - 49. [Abstract] [Full Text] [PDF]

				A. M. Sleeper, S. M. Sorscher, L. L. Dietrich, C. L. Loprinzi, and S. D. Thome Assessing Adjuvant Breast Cancer Therapy Benefit J. Clin. Oncol., June 15, 2001; 19(12): 3157 - 3159. [Full Text] [PDF]